Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Gilbert O. Fruhwirth"'
Autor:
R. Sumanth Iyer, Sarah R. Needham, Ioannis Galdadas, Benjamin M. Davis, Selene K. Roberts, Rico C. H. Man, Laura C. Zanetti-Domingues, David T. Clarke, Gilbert O. Fruhwirth, Peter J. Parker, Daniel J. Rolfe, Francesco L. Gervasio, Marisa L. Martin-Fernandez
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-21 (2024)
Abstract The Epidermal Growth Factor Receptor (EGFR) is frequently found to be mutated in non-small cell lung cancer. Oncogenic EGFR has been successfully targeted by tyrosine kinase inhibitors, but acquired drug resistance eventually overcomes the e
Externí odkaz:
https://doaj.org/article/85aaaaecf9114b44adb21e316e7276e8
Autor:
Elena Skourti, Alessia Volpe, Cameron Lang, Preeth Johnson, Fani Panagaki, Gilbert O. Fruhwirth
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionMicroRNAs are small non-coding RNAs and represent key players in physiology and disease. Aberrant microRNA expression is central to the development and progression of cancer, with various microRNAs proposed as potential cancer biomarkers
Externí odkaz:
https://doaj.org/article/c05f89262dde4d91a54cefcbc020765c
Autor:
Jacinta Jacob, Suchita Nadkarni, Alessia Volpe, Qi Peng, Sim L. Tung, Rosalind F. Hannen, Yasmin R. Mohseni, Cristiano Scotta, Federica M. Marelli-Berg, Robert I. Lechler, Lesley A. Smyth, Gilbert O. Fruhwirth, Giovanna Lombardi
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 20, Iss , Pp 324-336 (2021)
Regulatory T cells (Tregs) are emerging as a new cell-based therapy in solid organ transplantation. Adoptive transfer of Tregs has been shown preclinically to protect from graft rejection, and the safety of Treg therapy has been demonstrated in clini
Externí odkaz:
https://doaj.org/article/dcb780cc658b4eca9c8ec6f37d4a09f0
Autor:
Irene Rodriguez-Hernandez, Oscar Maiques, Leonie Kohlhammer, Gaia Cantelli, Anna Perdrix-Rosell, Joanne Monger, Bruce Fanshawe, Victoria L. Bridgeman, Sophia N. Karagiannis, Rosa M. Penin, Joaquim Marcolval, Rosa M. Marti, Xavier Matias-Guiu, Gilbert O. Fruhwirth, Jose L. Orgaz, Ilaria Malanchi, Victoria Sanz-Moreno
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-20 (2020)
Amoeboid cells are associated with melanoma invasive capacity. Here, the authors show that the WNT11-FZD7-DAAM1 pathway regulates tumour-initiating potential, invasion and metastasis lead by amoeboid cells in the invasive front of melanoma tumours.
Externí odkaz:
https://doaj.org/article/9e4929d31dc4466f83996eb59f8cabaf
Publikováno v:
Clinical and Translational Medicine, Vol 9, Iss 1, Pp 1-22 (2020)
Abstract The clinical application of ex vivo gene edited cell therapies first began a decade ago with zinc finger nuclease editing of autologous CD4+ T-cells. Editing aimed to disrupt expression of the human immunodeficiency virus co-receptor gene CC
Externí odkaz:
https://doaj.org/article/f2b2565acc644f159bf809fa7ae0af97
Autor:
Jacinta Jacob, Alessia Volpe, Qi Peng, Robert I. Lechler, Lesley A. Smyth, Giovanna Lombardi, Gilbert O. Fruhwirth
Publikováno v:
Molecules, Vol 28, Iss 3, p 1482 (2023)
Regulatory T cells (Tregs) are a promising candidate cell therapy to treat autoimmune diseases and aid the longevity of transplanted solid organs. Despite increasing numbers of clinical trials using human Treg therapy, important questions pertaining
Externí odkaz:
https://doaj.org/article/c2ce8a9f7b0347a791e20018dcb780c4
Autor:
Yasmin R. Mohseni, Sim L. Tung, Caroline Dudreuilh, Robert I. Lechler, Gilbert O. Fruhwirth, Giovanna Lombardi
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Cell therapy with polyclonal regulatory T cells (Tregs) has been translated into the clinic and is currently being tested in transplant recipients and patients suffering from autoimmune diseases. Moreover, building on animal models, it has been widel
Externí odkaz:
https://doaj.org/article/442bb64f507847b0b9c582ae08138ba7
Publikováno v:
Frontiers in Physiology, Vol 11 (2020)
Immunotherapy is a relatively new treatment regimen for cancer, and it is based on the modulation of the immune system to battle cancer. Immunotherapies can be classified as either molecular or cell-based immunotherapies, and both types have demonstr
Externí odkaz:
https://doaj.org/article/fd309ccfc3984c4ba142f713a35db05d
Autor:
Martin L. Read, Katie Brookes, Ling Zha, Selvambigai Manivannan, Jana Kim, Merve Kocbiyik, Alice Fletcher, Caroline M. Gorvin, George Firth, Gilbert O. Fruhwirth, Juan P. Nicola, Sissy Jhiang, Matthew D. Ringel, Moray J. Campbell, Kavitha Sunassee, Philip J. Blower, Kristien Boelaert, Hannah R. Nieto, Vicki E. Smith, Christopher J. McCabe
The sodium/iodide symporter (NIS) frequently shows diminished plasma membrane (PM) targeting in differentiated thyroid cancer (DTC), resulting in suboptimal radioiodide (RAI) treatment and poor prognosis. The mechanisms which govern the endocytosis o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0a757baf79e22f16a69b80be8a04fd2
https://doi.org/10.1101/2023.05.22.541733
https://doi.org/10.1101/2023.05.22.541733
Autor:
Tony Ng, Andrew N.J. Tutt, Paul Ellis, Sergio A. Quezada, Borivoj Vojnovic, Peter Lane, David R. Withers, Uzma Hasan, Leo M. Carlin, Frank McCaughan, Simon Ameer-Beg, Simon P. Poland, Cheryl E. Gillett, Sarah E. Pinder, Stewart G. Martin, Julie Owen, Manuel Rodriguez-Justo, Dominic Patel, Natalie Woodman, Paul R. Barber, Gilbert O. Fruhwirth, Anita Grigoriadis, Felix Wong, Farzana Noor, Patrycja Gazinska, Anthony Cheung, Peter Gordon, Victoria Male, Rachel Evans, James Monypenny, Katherine Lawler, Fabian Flores-Borja, Sheeba Irshad
Cancer cells tend to metastasize first to tumor-draining lymph nodes, but the mechanisms mediating cancer cell invasion into the lymphatic vasculature remain little understood. Here, we show that in the human breast tumor microenvironment (TME), the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17cbad6af0fb559eaeb880531f752848
https://doi.org/10.1158/0008-5472.c.6509700.v1
https://doi.org/10.1158/0008-5472.c.6509700.v1